## Highlights of This Issue 4303

### SPECIAL FEATURES

#### Editorial

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
<th>See article p.</th>
</tr>
</thead>
<tbody>
<tr>
<td>4305</td>
<td>Food and Oral Antineoplastics: More Than Meets the Eye</td>
<td>Rajul K. Jain, Satjit S. Brar, and Lawrence J. Lesko</td>
<td>4446</td>
</tr>
</tbody>
</table>

#### CCR Translations

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
<th>See article p.</th>
</tr>
</thead>
<tbody>
<tr>
<td>4308</td>
<td>Personalized Tamoxifen: A Step Closer but Miles To Go</td>
<td>Aditya Bardia and Vered Stearns</td>
<td>4468</td>
</tr>
<tr>
<td>4311</td>
<td>Arsenic Trioxide and the Phosphoinositide 3-Kinase/Akt Pathway in Chronic Lymphocytic Leukemia</td>
<td>Dennis J. Goussetis and Leonidas C. Platanias</td>
<td>4382</td>
</tr>
</tbody>
</table>

#### CCR New Strategies

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>4313</td>
<td>New Strategies in Pancreatic Cancer: Emerging Epidemiologic and Therapeutic Concepts</td>
<td>Donghui Li and James L. Abbruzzese</td>
<td></td>
</tr>
</tbody>
</table>

#### Molecular Pathways

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>4319</td>
<td>Overcoming Persistent Dependency on Androgen Signaling after Progression to Castration-Resistant Prostate Cancer</td>
<td>Masuo Yamaoka, Takahito Haru, and Masami Kusaka</td>
<td></td>
</tr>
<tr>
<td>4325</td>
<td>PI(3)King Apart PTEN's Role in Cancer</td>
<td>Siyuan Zhang and Dihua Yu</td>
<td></td>
</tr>
</tbody>
</table>

#### Report from the FDA

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>4331</td>
<td>U.S. Food and Drug Administration Approval: Ofatumumab for the Treatment of Patients with Chronic Lymphocytic Leukemia Refractory to Fludarabine and Alemtuzumab</td>
<td>Steven J. Lemery, Jenny Zhang, Mark D. Rothmann, Jun Yang, Justin Earp, Hong Zhao, Andrew McDougual, Anne Pilaro, Raymond Chiang, Joseph E. Gooteinberg, Patricia Keegan, and Richard Pazdur</td>
<td></td>
</tr>
</tbody>
</table>

---

### HUMAN CANCER BIOLOGY

- Transcriptional Profiling of Polycythemia Vera Identifies Gene Expression Patterns Both Dependent and Independent from the Action of JAK2V617F

- Meta-analysis of Neuroblastomas Reveals a Skewed ALK Mutation Spectrum in Tumors with MYCN Amplification
  - Sara De Brouwer, Katleen De Preeter, Candy Kumps, Piotr Zabrocki, Michael Porcu, Ellen M. Westerhout, Arjan Lakeman, Jo Vandesompele, Jasmien Hoebeeck, Tom Van Maerken, Anne De Paepe, Genevieve Laureys, Johannes H. Schulte, Alexander Schramm, Caroline Van Den Broecke, Joëlle Vermeulen, Nadine Van Roy, Klaus Beiske, Marleen Renard, Rosa Noguer, Olivier Delattre, Isabelle Janoueix-Lerosey, Per Kogner, Tommy Martinsson, Akira Nakagawara, Miki Ohira, Huib Caron, Angelika Eggert, Jan Cools, Rogier Versteeg, and Frank Speleman

- Upregulation of SOX9 in Lung Adenocarcinoma and Its Involvement in the Regulation of Cell Growth and Tumorigenicity
  - Shih-Sheng Jiang, Wen-Tsen Fang, Ya-Hsiue Hou, Shiu-Feng Huang, B. Linju Yen, Junn-Liang Chang, Shih-Miao Li, Hui-Ping Liu, Ying-Lan Liu, Chih-Ting Huang, Yu-Wei Li, Te-Hsuan Iang, Shih-Hsuan Chan, Su Jing Yang, Chao A. Hsiung, Cheng-Wen Wu, Lu-Hai Wang, and I-Shou Chang
Notch1 Expression Predicts an Unfavorable Prognosis and Serves as a Therapeutic Target of Patients with Neuroblastoma

Hsiu-Hao Chang, Hsinyu Lee, Ming-Kuan Hu, Po-Nien Tsao, Hsueh-Fen Juan, Min-Chuan Huang, Yu-Yin Shih, Bo-Jeng Wang, Yung-Ming Jeng, Christina Ling Chang, Shiu-Feng Huang, Yeou-Guang Tsay, Fon-Jou Hsieh, Kai-Hsin Lin, Wen-Ming Hsu, and Yung-Feng Liao

Prediction of Stage, Grade, and Survival in Bladder Cancer Using Genome-wide Expression Data: A Validation Study

Martin Lauss, Markus Ringnér, and Mattias Höglund

Preclinical and Clinical Evidence that Deoxy-2-[18F]fluoro-D-glucose Positron Emission Tomography with Computed Tomography Is a Reliable Tool for the Detection of Early Molecular Responses to Erlotinib in Head and Neck Cancer

Sébastien Vergez, Jean-Pierre Delord, Fabienne Thomas, Philippe Rochaix, Olivier Caselles, Thomas Filleron, Séverine Brillouet, Pierre Canal, Frédéric Courtin, and Ben C. Allal

Inconsistent Labeling of Food Effect for Oral Agents across Therapeutic Areas: Differences between Oncology and Non-Oncology Products

Soonmo Peter Kang and Mark J. Ratain

Histopathologic and Immunohistochemical Characterization of Rash to Human Epidermal Growth Factor Receptor 1 (HER1) and HER1/2 Inhibitors in Cancer Patients

Beatrice Nardone, Kimberly Nicholson, Marissa Newman, Joan Guitart, Pedram Gerami, Nicholas Talarico, Ximing J. Yang, Alfred Rademaker, Dennis P. West, and Mario E. Lacouture

Actinomycin D Decreases Mcl-1 Expression and Acts Synergistically with ABT-737 against Small Cell Lung Cancer Cell Lines

Haishan Xu and Geoffrey W. Krystal

Neurotensin Receptor 1 Determines the Outcome of Non–Small Cell Lung Cancer

Marco Alifano, Frédérique Souazé, Sandra Dupouy, Sophie Camilleri-Broët, Mohamad Younes, Sadi-Menad Ahmed-Zaid, Takashi Takahashi, Alessandra Cancellieri, Stefania Damiani, Maurizio Boarino, Philippe Broët, Lance D. Miller, Christian Gespach, Jean François Regnard, and Patricia Forgez

The Relationship between Prostate-Specific Antigen and Prostate Cancer Risk: The Prostate Biopsy Collaborative Group


Induction of B-Chronic Lymphocytic Leukemia Cell Apoptosis by Arsenic Trioxide Involves Suppression of the Phosphoinositide 3-Kinase/Akt Survival Pathway via c-jun-NH₂ Terminal Kinase Activation and PTEN Upregulation

Javier Redondo-Muñoz, Elizabeth Escobar-Díaz, Mercedes Hernández del Cerro, Atanasio Pandiella, María José Terol, José A. García-Marco, and Angeles García-Pardo

See commentary p. 4311

Actinomycin D Decreases Mcl-1 Expression and Acts Synergistically with ABT-737 against Small Cell Lung Cancer Cell Lines

Haishan Xu and Geoffrey W. Krystal

Neurotensin Receptor 1 Determines the Outcome of Non–Small Cell Lung Cancer

Marco Alifano, Frédérique Souazé, Sandra Dupouy, Sophie Camilleri-Broët, Mohamad Younes, Sadi-Menad Ahmed-Zaid, Takashi Takahashi, Alessandra Cancellieri, Stefania Damiani, Maurizio Boarino, Philippe Broët, Lance D. Miller, Christian Gespach, Jean François Regnard, and Patricia Forgez
The Effectiveness of Off-Protocol Adjuvant Chemotherapy for Patients with Urothelial Carcinoma of the Urinary Bladder

Preclinical and Clinical Estimates of the Basal Apoptotic Rate of a Cancer Predict the Amount of Apoptosis Induced by Subsequent Proapoptotic Stimuli
Lian Zhang, Brian D. Kavanagh, Andrew M. Thorburn, and D. Ross Camidge

CYP2D6 Polymorphisms as Predictors of Outcome in Breast Cancer Patients Treated with Tamoxifen: Expanded Polymorphism Coverage Improves Risk Stratification
Werner Schroth, Ute Hamann, Peter A. Fasching, Silke Dauser, Stefan Winter, Michel Eichelbaum, Matthias Schwab, and Hiltrud Brauch
See commentary p. 4308

Correction: Biobehavioral, Immune, and Health Benefits following Recurrence for Psychological Intervention Participants

ABOUT THE COVER
This is an original study providing, from preclinical models to patients, a reliable proof of $^{18}$FDG-PET/CT efficiency as a surrogate marker for the early evaluation of EGFR-TKI (erlotinib) efficacy that may improve diagnostic accuracy of molecular effect (ERK1/2). The image represents a facial sagittal section of an $^{18}$FDG-PET/CT of a patient with an oropharyngeal head and neck squamous cell carcinoma. It reveals a tumor $^{18}$FDG uptake before patient exposure to erlotinib. For further details, please see the article by Vergez and colleagues on page 4434 of this issue.